retatrutide benefits clinical trial retatrutide (“reta”) is an experimental weight-loss drug currently in Phase 3 trials. It's a once-weekly injection similar to Ozempic and Mounjaro—but more powerful. The reason comes down to how it works Today, we shared new data

Discuss with your GP or diabetes specialist what constitutes realistic treatment goals

Appetite suppression typically begins around week 3-4

Reta research products are often much cheaper than private Mounjaro pricing, especially after the UK Mounjaro price increase

IEEE Trans Med Imaging

2028 Translation and linguistic validation of the GENDER-Q into French for use in Canada Trisia Breitkopf 1 , Sylvie Cornacchi 1 , Ines Ndzana Siani 1 , Julia Sapin-Leduc 2 , Flavie Guibert-Pich 2 , Hanya Obsieh 1 , Charlene Rae 1 , Yi Wang 1 , Alexis Laungani 2 , Pierre Brassard 2 , Manraj Kaur 3 , Andrea Pusic 3 , Anne Klassen 1 1 Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada, 2 GrS Montral, Montral, Quebec, Canada, 3 Patient-Reported Outcomes and Values, & Experience Center (PROVE), Brigham and Womens Hospital, Harvard Medical School, Boston, USA Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :2028 Aims The GENDER-Q is a new patient-reported outcome measure (PROM) that measures outcomes in gender-affirming care

On average, 1 in 2 users paused or stopped their medication within the first 4 months